Gene: SYT13
Official Full Name: synaptotagmin 13provided by HGNC
Gene Summary: This gene encodes a member of the large synaptotagmin protein family. Family members have an extracellular N-terminal transmembrane domain and a cytoplasmic C terminus with two tandem C2 domains (C2A and C2B). Synaptotogmin family members can form homo- and heteromeric complexes with each other. They also have different biochemical properties and developmental profiles, and patterns of tissue distribution. Synaptotagmins function as membrane traffickers in multicellular organisms. Two alternatively spliced transcript variants that encode different protein isoforms have been described for this gene. [provided by RefSeq, Oct 2011]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO13606 | SYT13 Knockout cell line (HCT 116) | Human | SYT13 | 1:2~1:4 | Negative | Online Inquiry |
KO13607 | SYT13 Knockout cell line (A549) | Human | SYT13 | 1:3~1:4 | Negative | Online Inquiry |
SYT13 Gene Knockout Cell Lines are sophisticated biological tools designed to facilitate the study of the synaptotagmin-13 (SYT13) gene's role in cellular processes, particularly in neurotransmitter release and synaptic function. These knockout cell lines are generated through advanced CRISPR/Cas9 technology, effectively removing the SYT13 gene to create models that help researchers explore the gene's functions and associated signaling pathways.
The key mechanism of these cell lines lies in their ability to mimic pathological conditions resulting from the absence of the SYT13 gene. By utilizing these knockout models, researchers can investigate alterations in synaptic communication, calcium signaling, and the underlying mechanisms of neurodegenerative diseases. This makes SYT13 Gene Knockout Cell Lines invaluable in both basic research and therapeutic applications, empowering scientists to elucidate the molecular underpinnings of diseases such as Alzheimer's and other neurological disorders.
In terms of scientific importance, these cell lines can be pivotal in drug discovery and testing, allowing for the identification of novel therapeutic targets. Their use can significantly accelerate the translation of basic research findings into clinical applications, distinguishing them from traditional models that may not accurately mimic the gene's absence.
One of the primary advantages of SYT13 Gene Knockout Cell Lines is their specificity and reliability. Unlike alternative methods that may produce non-specific genetic modifications, the precise CRISPR/Cas9 approach offers consistent knockout efficiency and reproducibility, which is essential for obtaining reliable experimental results. Additionally, these cell lines are versatile as they can be tailored to various experimental conditions, catering to diverse research needs.
Researchers and clinicians will find SYT13 Gene Knockout Cell Lines to be valuable assets in advancing neurobiology research and therapeutic development. Their ability to deepen our understanding of synaptic mechanisms and potential treatment pathways represents a major step forward in the field.
Our company specializes in delivering high-quality biological products that empower researchers and enhance scientific discovery. With extensive expertise in cellular and molecular biology, we are committed to providing reliable tools that address the evolving needs of the scientific community.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.